Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01775358 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Safety Study of ALRN-5281 in Healthy Subjects
A Phase 1 study, sponsored by Aileron Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01775358 is a Phase 1 study that has completed, run by Aileron Therapeutics. The registered enrollment target is 33 participants.
The verdict
NCT01775358, a Phase 1 study, has completed, sponsored by Aileron Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of a single dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers.
Interventions
- DRUG ALRN-5281 0.015 mg/kg
- DRUG ALRN-5281 0.05 mg/kg
- DRUG ALRN-5281 0.15 mg/kg
- DRUG Placebo 0.015 mg/kg
- DRUG Placebo 0.05mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01775358
The ClinicalTrials.gov registry entry for NCT01775358 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aileron Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ALRN-5281 0.015 mg/kg is the first listed.
NCT01775358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01775358 about?
NCT01775358 is a clinical study titled "Phase 1 Safety Study of ALRN-5281 in Healthy Subjects". The primary objective of this study is to evaluate the safety and tolerability of a single dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers.
What is the current status of trial NCT01775358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2013-01. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01775358?
The interventions under investigation include: ALRN-5281 0.015 mg/kg (DRUG), ALRN-5281 0.05 mg/kg (DRUG), ALRN-5281 0.15 mg/kg (DRUG), Placebo 0.015 mg/kg (DRUG), Placebo 0.05mg/kg (DRUG).
Who is sponsoring clinical trial NCT01775358?
This trial is sponsored by Aileron Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.